Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center

Sex Transm Dis. 2007 Feb;34(2):65-8. doi: 10.1097/01.olq.0000225329.07765.d8.

Abstract

Background: We sought to evaluate the tolerability and feasibility of establishing an HIV postexposure prophylaxis (PEP) program at our hospital using the guidelines for children and adolescents after sexual assault.

Methods: This study was a prospective, nonrandomized observational study conducted from March 1999 until September 2002. Subjects (age <19 years) who presented to a pediatric emergency room within 72 hours of a sexual assault were eligible for enrollment. A 28-day PEP regimen of zidovudine and lamivudine was given.

Results: In all, 70 adolescents were evaluated and 33 (31 females and 2 males) were enrolled. The mean age of enrolled subjects was 15 years, 61% were Hispanic, 30% black, and 79% presented to the emergency room within 24 hours of assault. Vaginal exposure was the most common site of penetration (64% [21 of 33]), but 18% (6 of 33) reported anal penetration. Only 9 subjects (27%) took >or=90% of all the medications. All subjects who returned for follow up tested HIV-negative. Adverse events occurred in 48% (16 of 33) of subjects; the most common events were abdominal pain, nausea, or vomiting.

Conclusion: Poor adherence to medications and visits is a significant problem in PEP programs for sexually assaulted children and adolescents.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects
  • Child
  • Drug Combinations
  • Female
  • HIV / growth & development*
  • HIV Infections / prevention & control*
  • Humans
  • Lamivudine / administration & dosage*
  • Lamivudine / adverse effects
  • Male
  • Middle Aged
  • New York City
  • Patient Compliance
  • Prospective Studies
  • Regression Analysis
  • Sex Offenses*
  • Zidovudine / administration & dosage*
  • Zidovudine / adverse effects

Substances

  • Anti-HIV Agents
  • Drug Combinations
  • lamivudine, zidovudine drug combination
  • Lamivudine
  • Zidovudine